Claim 50% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Sun Pharmaceutical Industries Limited ( (IN:SUNPHARMA) ) just unveiled an update.
Sun Pharmaceutical Industries has launched UNLOXCYT (cosibelimab-ipdl) in the U.S. for adults with metastatic or locally advanced cutaneous squamous cell carcinoma who are not candidates for curative surgery or radiation, strengthening its presence in the oncology space. The treatment, described as an evolution in checkpoint inhibition, features a multifaceted mechanism of action as a novel anti–PD-L1 antibody, and its recently updated FDA label incorporates long-term clinical data showing durable efficacy, higher objective and complete response rates, and a stable safety profile, while the company is also rolling out the UNLOXCYT SUPPORT program to facilitate patient access and affordability from launch.
More about Sun Pharmaceutical Industries Limited
Sun Pharmaceutical Industries Limited is a global pharmaceutical company headquartered in India, with significant operations in North America. The company focuses on branded and specialty pharmaceuticals, including innovative oncology therapies, and targets both emerging and developed markets through its broad portfolio of prescription medicines.
Average Trading Volume: 83,740
Technical Sentiment Signal: Buy
Current Market Cap: 4080.1B INR
For a thorough assessment of SUNPHARMA stock, go to TipRanks’ Stock Analysis page.